Close Menu

By Edward Winnick

SAN FRANCISCO (GenomeWeb News) – Genomic Health officials today said that the firm has started the process of expanding its sales force by around 20 percent to help support the recent launch of its Oncotype DX DCIS Score test.

Speaking at the 30th Annual JP Morgan Healthcare Conference today, Genomic Health CEO Kim Popovits outlined the firm's efforts to expand the customer base for its Oncotype DX tests and announced that the company has launched a clinical validation study of its prostate cancer test.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A German shepherd called Nala has had her genome sequenced.

A coronavirus serology test garners Emergency Use Authorization from the US Food and Drug Administration, but the Los Angeles Times asks: how will tests like that be used?

Certain gene variants in conjunction with a healthy lifestyle may keep brains young, according to New Scientist.

In Science this week: increased CD8 T cell density and increased IFN-gamma response may indicate metastatic prostate cancer patients who will respond to immune checkpoint blockade therapy.

May
06
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.